OCTAVE-DUO is a multi-disease, randomised clinical trial to determine whether a re-boost vaccine strategy can induce an immune response in clinically vulnerable patients with proven inadequate response to SARS-CoV-2 vaccine.

Patients with solid cancer; lymphoid malignancies; immune-mediated rheumatic diseases; end stage kidney disease; chronic liver disease; inflammatory bowel disease on immune suppressive therapy; haematopoietic stem cell transplant; and primary immunodeficiency who have received two doses of SARS-CoV-2 vaccine but have proven inadequate response to SARS-CoV-2 vaccine attending specialist clinics across the UK will be recruited. 

OCTAVE-DUO is a collaborative research project involving academic partners from the Universities of Glasgow, Birmingham, Oxford, Imperial College London and the IMPACT network. The project is funded by UK Research and Innovation (UKRI).